Bis(2,2′-bipyridine)[1,9-bis(diphenylphos­phanyl)-1,2,3,4,6,7,8,9-octahydropyrim­ido[1,2-a]pyrimidin-5-ium]ruthenium(II) hexa­fluorido­phosphate dibromide di­chloro­methane disolva...

Por Shang, Congcong, Vendier, Laure, Sutra, Pierre, Igau, Alain
Publicado em 2013

Alectinib treatment response in lung adenocarcinoma patient with novel EML4‐ALK variant

Por Song, Peng, Zhang, Jingcheng, Shang, Congcong, Zhang, Li
Publicado no Thorac Cancer (2018)

Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors

Por Song, Peng, Zhang, Jingcheng, Shang, Congcong, Zhang, Li
Publicado no Sci Rep (2019)

Curative effect assessment of immunotherapy for non‐small cell lung cancer: The “blind area” of Immune Response Evaluation Criteria in Solid Tumors (iRECIST)

Por Song, Peng, Zhang, Jingcheng, Shang, Congcong, Zhang, Li
Publicado no Thorac Cancer (2019)

Author Correction: Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors

Por Song, Peng, Zhang, Jingcheng, Shang, Congcong, Zhang, Li
Publicado no Sci Rep (2020)